Therefore, early and accurate prediction of tumor shrinkage patterns in HR+/HER2- BC patients after NAC is critical for ensuring patients benefit from NAC with the goal of breast conservation while avoiding overtreatment and ineffective therapy. Here, ERBB2 is linked to breast cancer.